2019 American Transplant Congress
Evidence to Support the Use of Kidney Allograft Function as a Clinical Trial Outcome Measure
Nephrology, University of British Columbia, Vancouver, BC, Canada
*Purpose: As a biomarker, kidney allograft function has been rejected as clinical trial outcome measure because it is not predictive of allograft survival. In this…2019 American Transplant Congress
Clazakizumab (CLZ, Anti-IL-6 Monoclonal Antibody) Treatment of Patients (Pts) with Chronic Antibody-Mediated Rejection (cABMR) Reduces Total Immunoglobulin (Ig) and Anti-HLA IgG Antibody Levels
Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: We have recently reported successful use of Tocilizumab (TCZ), an anti-IL-6 receptor (R) monoclonal antibody, for cABMR treatment in HLA-sensitized kidney transplant (KTx) Pts.…2019 American Transplant Congress
Impact Of The Provision Of Transplant Information On Access To First And Repeat Kidney Transplantation
Nephrology, University of British Columbia, Vancouver, BC, Canada
*Purpose: To determine whether the provision and relative impact of transplant information differs in incident ESRD patients and patients with a history of previous transplant…2019 American Transplant Congress
Estimated vs. Actual Graft Failure and Patient Survival after Kidney Transplantation
*Purpose: The purpose of this study was to examine the difference between the estimated and actual values of graft survival and patient survival in kidney…2019 American Transplant Congress
The Effect of a Novel Dosing Protocol for the De Novo Use of LCP Tacrolimus in Kidney Transplant Recipients Managed on a Steroid-Free Maintenance Immunosuppression Regimen
*Purpose: It is not known if an extended release formulation of tacrolimus (LCPT, Envarsus XR®) can be successfully dosed to achieve an early therapeutic trough…2019 American Transplant Congress
Assessment of Proteinuria Reported as Adverse Events in De Novo Renal Transplant Recipients Receiving an Everolimus-Based Regimen: 24-Month Results from TRANSFORM
1TRANSFORM Study Group, Basel, Switzerland, 2Novartis Pharma AG, Basel, Switzerland
*Purpose: mTOR inhibitors (eg, everolimus [EVR]), are thought to increase the risk of post-transplant (Tx) proteinuria (PU). Here, we assess PU onset and outcomes in…2019 American Transplant Congress
Comparison of Initial Sirolimus (SRL) and Everolimus (EVR) Exposure Patterns in Kidney Transplant Recipients
Hospital do Rim, Nephrology Division, EPM - UNIFESP, São Paulo, Brazil
*Purpose: Despite distinct pharmacokinetic properties, SRL and EVR bind to the same intracellular target protein, suggesting that equivalent blood concentrations may exert similar pharmacodynamic effect.*Methods:…2019 American Transplant Congress
Illustration of Renal Recovery in SLK with Utilization of Most Recent Allocation Criteria
Henry Ford Hospital Detroit, Detroit, MI
*Purpose: Single Center review of Renal recovery in Simultaneous Liver Kidney Transplantation (SLKT) in patients who were approved for SLK based on the recent UNOS…2019 American Transplant Congress
Comparable Outcomes of Deceased Donor Liver Transplant Outcomes in Recipients with Previous Abdominal Surgery (PAS) after Pre Listing Surgical Categorization. A Propensity-Score Matched Pair Analysis
Department of Transplant Surgery, Ochsner Medical Center, New Orleans, LA
*Purpose: Few studies have evaluated the impact of previous abdominal surgery (PAS) on deceased donor liver transplantation-(DDLT). Furthermore, there is no evidence of impact of…2019 American Transplant Congress
Use of a CMV Specific T Cell Immunity Assay in Late-Onset CMV Infection
*Purpose: To describe our clinical experience using a CMV Specific Cell Mediated Immunity (CMI) assay in solid organ transplant (SOT) recipients with late-onset CMV, defined…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 214
- Next Page »